High Response Rate in Marginal Zone Lymphoma Patients: Initial Data Shows ZYNLONTA® Efficacy

Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient ach...

May 06, 2024 | Monday | News
Walgreens and Boehringer Ingelheim Forge Strategic Partnership to Democratize Clinical Trials

Walgreens and Boehringer Ingelheim announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusiv...

May 03, 2024 | Friday | News
Beyfortus (nirsevimab) Proves Potent Against RSV Hospitalizations in Infants

New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the...

May 03, 2024 | Friday | News
HiberCell Initiates Phase 1b Trial for Combination Therapy in Advanced Kidney Cancer

HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, is pleased to announ...

May 02, 2024 | Thursday | News
NKGen Biotech's SNK01 NK Cell Therapy Clears FDA IND Hurdle for Parkinson’s

The Company expects to initiate a Phase 1 clinical trial in PD in 2H 2024. NKGen Biotech, Inc. , a clinical-stage biotechnology company focused on the dev...

April 30, 2024 | Tuesday | News
Abzena Introduces EpiScreen® 2.0: Transforms Immunogenicity Assessment for Advanced Therapeutics

Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScree...

April 29, 2024 | Monday | News
Hyundai Bioscience Announces Clinical Development Plan for Oral Niclosamide Metabolic Anticancer Drug Targeting p53 Gene Mutations

Hyundai Bioscience announced its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cance...

April 25, 2024 | Thursday | News
Gain Therapeutics Reports Positive Results from Phase 1 Study of GT-02287, Showcasing Promising Safety and Tolerability Profile

Gain Therapeutics, a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapi...

April 25, 2024 | Thursday | News
Shanghai Junshi Biosciences' Toripalimab NDA Accepted by Hong Kong DO for Groundbreaking Nasopharyngeal Carcinoma Treatment

Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel...

April 25, 2024 | Thursday | News
EXO Biologics Raises EUR 16M for Exosome Therapy Development

    EXO Biologics, a clinical-stage biotech and a pioneer in developing exosome-based therapies, announces the successful securing of a t...

April 24, 2024 | Wednesday | News
Sanofi's Breakthrough BTK Inhibitor Shows Promise for Patients with Persistent and Chronic ITP, Regulatory Submissions Expected Soon

Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombo...

April 23, 2024 | Tuesday | News
Ipsen Strikes Option Agreement with Skyhawk for Exclusive Global Rights to Novel Neurological Disease Candidates

Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development candida...

April 22, 2024 | Monday | News
SNIPR Biome Receives CARB-X Funding for CRISPR Medicine Trials

  SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene the...

April 22, 2024 | Monday | News
Australian Biotech Firm Ferronova Initiates Clinical Trial for FerroTrace® Nanoparticle Technology in Gastric and Oesophageal Cancers

Australian biotech company Ferronova has announced the initiation of a clinical trial of the company’s FerroTrace® nanoparticle technology in pat...

April 10, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close